Aconin is the world’s first long-acting HIV fusion enzyme inhibitor and the first original new anti-HIV drug in China, with independent intellectual property rights. The main role of Aconin is to combine with other antiretroviral drugs. Aconin is effective against both prevalent HIV and drug-resistant viruses, with few side effects and low dosing frequency, requiring only one shot a week. For patients with AIDS, antiviral treatment is the first priority. Because HIV can attack the body’s immune function, mainly the most important CD4T lymphocytes, causing the body’s immune function to be low and prone to various viruses, it can also develop into a malignant tumor that can be life-threatening. It can also cause diseases of various organ systems, such as cardiovascular system, respiratory system, urinary system, digestive system and other multi-system diseases.